Skip to content
Search

Latest Stories

Class 2 recall for Olopatadine eye drops

Pb Staff writer
By Pb Staff writerApr 12, 2022
Pb Staff writer
See Full Bio

The Medicines and Healthcare products Regulatory Agency has issued a class 2 medicines recall notice for Olopatadine USV 1mg/ml eye drops.

Specific batches of this product are being recalled by USV UK Limited as a precautionary measure due to the identification of out of specification results for impurities during routine stability testing.

USV UK Limited are recalling the affected batches as a precautionary measure due to out of specification results for impurities during routine stability testing.

Batch NumberExpiry DatePack SizeFirst Distributed
3500020107/20235ml14 July 2021
3500020207/20235ml27 July 2021
3500020307/20235ml5 August 2021
3500020407/20235ml29 November 2021
3500020607/20235ml23 July 2021

While the company’s investigation is on-going, community pharmacy contractors should stop supplying the specified batches immediately, quarantine all remaining stock, and return it to their supplier using their supplier's approved process.

medicines and healthcare products regulatory agency; mhra; drugs stability testing; usv uk limited; olopatadine

Related News

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer
News

NICE approves twice-a-day tablet for advanced breast cancer

Regulators warn pharmacies over advertising of weight management medicines

Do not promote weight management medicines to the public: Regulators warn pharmacies

Community pharmacies should stop offering services for free
News

“Stop doing things for free”- Pharmacy leaders urge contractors

GPhC cautions pharmacies over supply of Lemon Bottle, alternative therapies

Pharmacies cautioned over supply of 'Lemon Bottle' and alternative therapies

More For You

ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine, survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less
NHS pharmacy funding not enough 2025: £3.073B deal with £1.99B gap fuels reform debate.

Funding alone isn’t going to be enough to save community pharmacy

Photo credit: gettyimages

New funding contract ‘not enough’ to release the sector from financial blackhole

After almost a year without an agreement, a new funding contract for community pharmacy was finally announced yesterday (31 March).

The settlement raises the baseline annual funding for the Community Pharmacy Contractual Framework (CPCF) in 2025/26 to £3.073 billion, with an additional £215 million secured to continue Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
© Copyright 2025 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc